{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:12:10Z","timestamp":1790518330863,"version":"4.1.0"},"reference-count":46,"publisher":"Japanese Pharmacological Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Pharmacol Sci"],"published-print":{"date-parts":[[2014]]},"DOI":"10.1254\/jphs.13141fp","type":"journal-article","created":{"date-parts":[[2014,1,30]],"date-time":"2014-01-30T23:08:29Z","timestamp":1391123309000},"page":"180-191","source":"Crossref","is-referenced-by-count":37,"title":["Downregulation of CYP3A and P-Glycoprotein in the Secondary Inflammatory Response of Mice With Dextran Sulfate Sodium\u2013Induced Colitis and Its Contribution to Cyclosporine A Blood Concentrations"],"prefix":"10.1254","volume":"124","author":[{"given":"Shoji","family":"Kawauchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikuya","family":"Miki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuneo","family":"Hamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihito","family":"Tanahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeto","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"332","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Zhou S, Chan SY, Goh BC, Chan E, Duan W, Huang M, et al. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet. 2005;44:279\u2013304.","DOI":"10.2165\/00003088-200544030-00005"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, Zeldin DC. The human intestinal cytochrome P450 \u201cpie\u201d. Drug Metab Dispos. 2006;34:880\u2013886.","DOI":"10.1124\/dmd.105.008672"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Jin M, Shimada T, Yokogawa K, Nomura M, Ishizaki J, Piao Y, et al. Site-dependent contributions of P-glycoprotein and CYP3A to cyclosporin A absorption, and effect of dexamethasone in small intestine of mice. Biochem Pharmacol. 2006;72:1042\u20131050.","DOI":"10.1016\/j.bcp.2006.07.020"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9:215\u2013236.","DOI":"10.1038\/nrd3028"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Smit JW, Schinkel AH, Weert B, Meijer DK. Hepatobiliary and intestinal clearance of amphiphilic cationic drugs in mice in which both mdr1a and mdr1b genes have been disrupted. Br J Pharmacol. 1998;124:416\u2013424.","DOI":"10.1038\/sj.bjp.0701845"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Kivist\u00f6 KT, Niemi M, Fromm MF. Functional interaction of intestinal CYP3A4 and P-glycoprotein. Fundam Clin Pharmacol. 2004;18:621\u2013626.","DOI":"10.1111\/j.1472-8206.2004.00291.x"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Jin M, Shimada T, Yokogawa K, Nomura M, Kato Y, Tsuji A, et al. Contributions of intestinal P-glycoprotein and CYP3A to oral bioavailability of cyclosporin A in mice treated with or without dexamethasone. Int J Pharm. 2006;309:81\u201386.","DOI":"10.1016\/j.ijpharm.2005.11.015"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 van Waterschoot RA, Lagas JS, Wagenaar E, van der Kruijssen CM, van Herwaarden AE, Song JY, et al. Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity. Cancer Res. 2009;69:8996\u20139002.","DOI":"10.1158\/0008-5472.CAN-09-2915"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Masubuchi Y, Horie T. Endotoxin-mediated disturbance of hepatic cytochrome P450 function and development of endotoxin tolerance in the rat model of dextran sulfate sodium-induced experimental colitis. Drug Metab Dispos. 2004;32:437\u2013441.","DOI":"10.1124\/dmd.32.4.437"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Chaluvadi MR, Nyagode BA, Kinloch RD, Morgan ET. TLR4-dependent and -independent regulation of hepatic cytochrome P450 in mice with chemically induced inflammatory bowel disease. Biochem Pharmacol. 2009;77:464\u2013471.","DOI":"10.1016\/j.bcp.2008.10.029"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Colli A, Buccino G, Cocciolo M, Parravicini R, Scaltrini G. Disposition of a flow-limited drug (lidocaine) and a metabolic capacity-limited drug (theophylline) in liver cirrhosis. Clin Pharmacol Ther. 1988;44:642\u2013649.","DOI":"10.1038\/clpt.1988.206"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Piquette-Miller M, Pak A, Kim H, Anari R, Shahzamani A. Decreased expression and activity of P-glycoprotein in rat liver during acute inflammation. Pharm Res. 1998;15:706\u2013711.","DOI":"10.1023\/A:1011962818051"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Frye RF, Zgheib NK, Matzke GR, Chaves-Gnecco D, Rabinovitz M, Shaikh OS, et al. Liver disease selectively modulates cytochrome P450-mediated metabolism. Clin Pharmacol Ther. 2006;80:235\u2013245.","DOI":"10.1016\/j.clpt.2006.05.006"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347:417\u2013429.","DOI":"10.1056\/NEJMra020831"},{"key":"15","unstructured":"15 Kimmelstein P, Large HL, Vemner HD. Liver damage inulcerative colitis. Am J Pathol. 1952;28:259\u2013279."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Broom\u00e9 U, Glaumann H, Hellers G, Nilsson B, S\u00f6rstad J, Hultcrantz R. Liver disease in ulcerative colitis: an epidemiological and follow up study in the county of Stockholm. Gut. 1994;35:84\u201389.","DOI":"10.1136\/gut.35.1.84"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Memon MI, Memon B, Memon MA. Hepatobiliary manifestations of inflammatory bowel disease. HPB Surg. 2000;11:363\u2013371.","DOI":"10.1155\/2000\/98384"},{"key":"18","unstructured":"18 Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest. 1993;69:238\u2013249."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Yoshihara K, Yajima T, Kubo C, Yoshikai Y. Role of interleukin 15 in colitis induced by dextran sulfate sodium in mice. Gut. 2006;55:334\u2013341.","DOI":"10.1136\/gut.2005.076000"},{"key":"20","unstructured":"20 Krawisz JE, Sharon P, Stenson WF. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology. 1984;87:1344\u20131350."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Okayama M, Hayashi S, Aoi Y, Nishio H, Kato S, Takeuchi K. Aggravation by selective COX-1 and COX-2 inhibitors of dextran sulfate sodium (DSS)-induced colon lesions in rats. Dig Dis Sci. 2007;52:2095\u20132103.","DOI":"10.1007\/s10620-006-9597-z"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402\u2013408.","DOI":"10.1006\/meth.2001.1262"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Buyse M, Radeva G, Bado A, Farinotti R. Intestinal inflammation induces adaptation of P-glycoprotein expression and activity. Biochem Pharmacol. 2005;69:1745\u20131754.","DOI":"10.1016\/j.bcp.2005.03.025"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Beresini MH, Davalian D, Alexander S, Toton-Quinn R, Barnett B, Cerelli MJ, et al. Evaluation of EMIT Cyclosporine Assay for use with whole blood. Clin Chem. 1993;39:2235\u20132241.","DOI":"10.1093\/clinchem\/39.11.2235"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology. 1990;98:694\u2013702.","DOI":"10.1016\/0016-5085(90)90290-H"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Gaudio E, Taddei G, Vetuschi A, Sferra R, Frieri G, Ricciardi G, et al. Dextran sulfate sodium (DSS) colitis in rats: clinical, structural, and ultrastructural aspects. Dig Dis Sci. 1999;44:1458\u20131475.","DOI":"10.1023\/A:1026620322859"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Reed KL, Fruin AB, Gower AC, Gonzales KD, Stucchi AF, Andry CD, et al. NF-kappaB activation precedes increases in mRNA encoding neurokinin-1 receptor, proinflammatory cytokines, and adhesion molecules in dextran sulfate sodium-induced colitis in rats. Dig Dis Sci. 2005;50:2366\u20132378.","DOI":"10.1007\/s10620-005-3066-y"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Alex P, Zachos NC, Nguyen T, Gonzales L, Chen TE, Conklin LS, et al. Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis. Inflamm Bowel Dis. 2009;15:341\u2013352.","DOI":"10.1002\/ibd.20753"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Egger B, Bajaj-Elliott M, MacDonald TT, Inglin R, Eysselein VE, B\u00fcchler MW. Characterisation of acute murine dextran sodium sulphate colitis: cytokine profile and dose dependency. Digestion. 2000;62:240\u2013248.","DOI":"10.1159\/000007822"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Brooke BN, Slaney G. Portal bacteraemia in ulcerative colitis. Lancet. 1958;1:1206\u20131207.","DOI":"10.1016\/S0140-6736(58)91910-X"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Eade MN, Brook BN. Portal bacteraemia in cases of ulcerative colitis submitted to colectomy. Lancet. 1969;1:1008\u20131009.","DOI":"10.1016\/S0140-6736(69)91802-9"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Masubuchi Y, Enoki K, Horie T. Down-regulation of hepatic cytochrome P450 enzymes in rats with trinitrobenzene sulfonic acid-induced colitis. Drug Metab Dispos. 2008;36:597\u2013603.","DOI":"10.1124\/dmd.107.018754"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Lorentsen KJ, Hendrix CW, Collins JM, Kornhauser DM, Petty BG, Klecker RW, et al. Dextran sulfate is poorly absorbed after oral administration. Ann Intern Med. 1989;111:561\u2013566.","DOI":"10.7326\/0003-4819-111-7-561"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Trauner M, Boyer JL. Bile salt transporters: molecular characterization, function, and regulation. Physiol Rev. 2003;83:633\u2013671.","DOI":"10.1152\/physrev.00027.2002"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Faber KN, M\u00fcller M, Jansen PL. Drug transport proteins in the liver. Adv Drug Deliv Rev. 2003;55:107\u2013124.","DOI":"10.1016\/S0169-409X(02)00173-4"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Zollner G, Wagner M, Moustafa T, Fickert P, Silbert D, Gumhold J, et al. Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter-alpha\/beta in the adaptive response to bile acids. Am J Physiol Gastrointest Liver Physiol. 2006;290:G923\u2013G932.","DOI":"10.1152\/ajpgi.00490.2005"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37 Hartmann G, Kim H, Piquette-Miller M. Regulation of the hepatic multidrug resistance gene expression by endotoxin and inflammatory cytokines in mice. Int Immunopharmacol. 2001;1:189\u2013199.","DOI":"10.1016\/S0162-3109(00)00271-X"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 Hartmann G, Cheung AK, Piquette-Miller M. Inflammatory cytokines, but not bile acids, regulate expression of murine hepatic anion transporters in endotoxemia. J Pharmacol Exp Ther. 2002;303:273\u2013281.","DOI":"10.1124\/jpet.102.039404"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39 Geier A, Dietrich CG, Voigt S, Ananthanarayanan M, Lammert F, Schmitz A, et al. Cytokine-dependent regulation of hepatic organic anion transporter gene transactivators in mouse liver. Am J Physiol Gastrointest Liver Physiol. 2005;289:G831\u2013G841.","DOI":"10.1152\/ajpgi.00307.2004"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40 Cerveny L, Svecova L, Anzenbacherova E, Vrzal R, Staud F, Dvorak Z, et al. Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways. Drug Metab Dispos. 2007;35:1032\u20131041.","DOI":"10.1124\/dmd.106.014456"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41 Li H, Wang H. Activation of xenobiotic receptors: driving into the nucleus. Expert Opin Drug Metab Toxicol. 2010;6:409\u2013426.","DOI":"10.1517\/17425251003598886"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42 Kalitsky-Szirtes J, Shayeganpour A, Brocks DR, Piquette-Miller M. Suppression of drug-metabolizing enzymes and efflux transporters in the intestine of endotoxin-treated rats. Drug Metab Dispos. 2004;32:20\u201327.","DOI":"10.1124\/dmd.32.1.20"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43 Gu X, Ke S, Liu D, Sheng T, Thomas PE, Rabson AB, et al. Role of NF-kappaB in regulation of PXR-mediated gene expression: a mechanism for the suppression of cytochrome P-450 3A4 by proinflammatory agents. J Biol Chem. 2006;281:17882\u201317889.","DOI":"10.1074\/jbc.M601302200"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44 Lee CM, Kim BY, Li L, Morgan ET. Nitric oxide-dependent proteasomal degradation of cytochrome P450 2B proteins. J Biol Chem. 2008;283:889\u2013898.","DOI":"10.1074\/jbc.M708821200"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45 Nawa A, Fujita-Hamabe W, Tokuyama S. Involvement of ubiquitination in the decrease of intestinal P-glycoprotein in a streptozotocin-induced diabetic mouse model. Drug Metab Pharmacokinet. 2012;27:548\u2013552.","DOI":"10.2133\/dmpk.DMPK-11-NT-152"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46 Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK, Schmiedlin-Ren P, et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther. 1997;62:248\u2013260.","DOI":"10.1016\/S0009-9236(97)90027-8"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jphs\/124\/2\/124_13141FP\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T15:10:45Z","timestamp":1621437045000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jphs\/124\/2\/124_13141FP\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1254\/jphs.13141fp","relation":{},"ISSN":["1347-8613","1347-8648"],"issn-type":[{"value":"1347-8613","type":"print"},{"value":"1347-8648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}